Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational studyAndrew Ip, Stuart L. Goldberg, Donald A. Berry et al.|PLoS ONE|2020Cited by 144
Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients – An Observational StudyAndrew Ip, Stuart L. Goldberg, Donald A. Berry et al.|medRxiv|2020Cited by 69
Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19Charles R. Vasquez, Steven G. Coca, M.G.S. Shashaty et al.|CHEST Journal|2021Cited by 40
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)Iván O. Rosas, Min Bao, Norbert Bräu et al.|EClinicalMedicine|2022Cited by 37
Association of Surge Conditions with Mortality Among Critically Ill Patients with COVID-19Adam Keene, Lili Chan, Andrew J. Admon et al.|Journal of Intensive Care Medicine|2021Cited by 17